On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way. Cobenfy (xanomeline and trospium chloride) capsules are the first antipsychotic drug approved to target cholinergic receptors. All other treatments available for schizophrenia target the dopamine receptors.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other antipsychotics.

The US Food and Drug Administration FDA has approved French pharmaceutical company Sanofi Dupixent an anti-bronchitis drug for smokersAcc